BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Pozen, Inc. 

6330 Quadrangle Drive, Suite 240

Chapel Hill  North Carolina  27514  U.S.A.
Phone: 919-490-0012 Fax:


SEARCH JOBS


Industry
Biotechnology






 Company News
Pozen, Inc. (POZN) to Host Analyst and Investor Update Webcast 4/10/2013 9:42:37 AM    More...
Pozen, Inc. (POZN) Announces Results From a Burden of Cardiovascular Disease Study: a Managed Care Perspective 4/5/2013 9:56:27 AM    More...
Pozen, Inc. (POZN) to Present at the 25th Annual ROTH Conference 3/7/2013 6:24:46 AM    More...
Pozen, Inc. (POZN) Announces March 6th Webcast of Fourth Quarter and Year End 2012 Results 2/27/2013 6:41:46 AM    More...
Pozen, Inc. (POZN) Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference 2/8/2013 9:47:00 AM    More...
Pozen, Inc. (POZN) Presents Positive Phase 3 Results 2/8/2013 7:38:08 AM    More...
Pozen, Inc. (POZN) Announces Positive Results for the PA8140-102 Bioavailability Study 11/16/2012 9:39:33 AM    More...
Pozen, Inc. (POZN) Reports Positive Test Results for Proposed Aspirin Therapy 11/7/2012 7:48:40 AM    More...
Pozen, Inc. (POZN) Announces PA32540 Provides Superior Antiplatlet Effects Over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx") 8/29/2012 10:17:54 AM    More...
Pozen, Inc. (POZN) Provides Update on Its PA Program and Results of Its Type A Meeting With the FDA 8/24/2012 8:37:50 AM    More...
12345678910...